Drug Profile
Research programme: short interfering RNA-based therapeutics - Silence Therapeutics
Alternative Names: GalNAc-siRNA - Silence Therapeutics; ICS-283; Research programme: RNAi-based therapeutics -Intradigm/QiagenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Intradigm Corporation
- Developer Intradigm Corporation; OPKO Health; Silence Therapeutics
- Class Amino sugars; Cardiovascular therapies; Drug conjugates; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acromegaly; Alcoholism; Metabolic disorders
- Discontinued Age-related macular degeneration; Cancer; Coronavirus infections; Diabetic retinopathy
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Acromegaly in United Kingdom (Parenteral)
- 28 Apr 2021 No recent reports of development identified for research development in Alcoholism in United Kingdom (Parenteral)
- 28 Nov 2020 No recent reports of development identified for research development in Metabolic-disorders in United Kingdom (Parenteral)